COVID-19 Among Patients With Inflammatory Rheumatic Diseases.

Autor:	Esatoglu SN; Department of Rheumatology, Gaziosmanpasa Research and Training Hospital, Health Sciences University, Istanbul, Turkey., Tascilar K; Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University Erlangen- Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany., Babaoğlu H; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey., Bes C; Department of Rheumatology, Sadi Konuk Education and Research Hospital, Health Sciences University, Istanbul, Turkey., Yurttas B; Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey., Akar S; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Izmir Katip Celebi University, Izmir, Turkey., Pehlivan O; Department of Rheumatology, Umraniye Training and Research Hospital, Istanbul, Turkey., Akleylek C; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, TC Demiroglu Bilim University, Istanbul, Turkey., Tecer D; Department of Rheumatology, Gülhane Faculty of Medicine, Health Sciences University, Ankara, Turkey., Seyahi E; Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey., Yuce-Inel T; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey., Alpay-Kanitez N; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Koc University, Istanbul, Turkey., Bodakci E; Department of Rheumatology, Eskisehir City Hospital, Eskisehir, Turkey., Tekgoz E; Department of Rheumatology, Gülhane Faculty of Medicine, Health Sciences University, Ankara, Turkey., Colak S; Department of Rheumatology, Gülhane Faculty of Medicine, Health Sciences University, Ankara, Turkey., Bolek EC; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Koca SS; Division of Rheumatology, Department of Internal Medicine, School of Medicine, Firat University, Elazig, Turkey., Kalyoncu U; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey., Icacan OC; Department of Rheumatology, Sadi Konuk Education and Research Hospital, Health Sciences University, Istanbul, Turkey., Ugurlu S; Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey., Oz HE; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Izmir Katip Celebi University, Izmir, Turkey., Hamuryudan V; Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey., Hatemi G; Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2021 Apr 16; Vol. 12, pp. 651715. Date of Electronic Publication: 2021 Apr 16 (Print Publication: 2021).
DOI:	10.3389/fimmu.2021.651715
Abstrakt:	Background: The course of novel coronavirus disease 2019 (COVID-19) has been of special concern in patients with inflammatory rheumatic diseases (IRDs) due to the immune dysregulation that may be associated with these diseases and the medications used for IRDs, that may affect innate immune responses. Objective: In this cohort study, we aimed to report the disease characteristics and variables associated with COVID-19 outcome among Turkish patients with IRDs. Methods: Between April and June, 2020, 167 adult IRD patients with COVID-19 were registered from 31 centers in 14 cities in Turkey. Disease outcome was classified in 4 categories; (i) outpatient management, (ii) hospitalization without oxygen requirement, (iii) hospitalization with oxygen requirement, and (iv) intensive care unit (ICU) admission or death. Multivariable ordinal logistic regression analysis was conducted to determine variables associated with a worse outcome. Results: 165 patients (mean age: 50 ± 15.6 years, 58.2% female) were included. Twenty-four patients (14.5%) recovered under outpatient management, 141 (85.5%) were hospitalized, 49 (30%) required inpatient oxygen support, 22 (13%) were treated in the ICU (17 received invasive mechanic ventilation) and 16 (10%) died. Glucocorticoid use (OR: 4.53, 95%CI 1.65-12.76), chronic kidney disease (OR: 12.8, 95%CI 2.25-103.5), pulmonary disease (OR: 2.66, 95%CI 1.08-6.61) and obesity (OR: 3.7, 95%CI 1.01-13.87) were associated with a worse outcome. Biologic disease-modifying antirheumatic drugs (DMARDs) do not seem to affect COVID-19 outcome while conventional synthetic DMARDs may have a protective effect (OR: 0.36, 95%CI 0.17-0.75). Estimates for the associations between IRD diagnoses and outcome were inconclusive. Conclusions: Among IRD patients with COVID-19, comorbidities and glucocorticoid use were associated with a worse outcome, while biologic DMARDs do not seem to be associated with a worse outcome. Competing Interests: KT has served as a speaker for Gilead. GH has received grant/research support from Celgene and has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Esatoglu, Tascilar, Babaoğlu, Bes, Yurttas, Akar, Pehlivan, Akleylek, Tecer, Seyahi, Yuce-Inel, Alpay-Kanitez, Bodakci, Tekgoz, Colak, Bolek, Koca, Kalyoncu, Icacan, Ugurlu, Oz, Hamuryudan, Hatemi and the Turkish Society for Rheumatology COVID-19 Registry Investigators.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu